Molecular characterization of the idiopathic hypereosinophilic syndrome
(HES) in 35 French patients with normal conventional cytogenetics.
The report reviews pipeline therapeutics for Hypereosinophilic Syndrome
by companies and universities/research institutes based on information derived from company and industry-specific sources
Wells' syndrome as a manifestation of hypereosinophilic syndrome
Idiopathic hypereosinophilic syndrome
associated with cutaneous infarction and deep venous thrombosis.
Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome
12] concentrations frequently occur with myeloproliferative disorders, hypereosinophilic syndromes
, and hepatic diseases (3-11).
Coverage includes techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP 1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome
and chronic eosinophilic leukemia, classification of acute myeloid leukemia by DNA- oligonucleotide microarrays, detection of the V617F JAK2 mutation in myeloproliferative disorders, gene rearrangements, FLT3 mutations andWT-1 overexpression.
It also reviews key players involved in the therapeutic development for Hypereosinophilic Syndrome
The purpose of this review is to provide an overview of the differential diagnosis for eosinophilia, to recommend specific steps for the pathologist evaluating blood and bone marrow samples, and to emphasize 2 important causes of eosinophilia that require specific ancillary tests for diagnosis: myeloproliferative neoplasm with PDGFRA rearrangement and lymphocyte-variant hypereosinophilic syndrome
In addition, the imatinib mesylate tablets have been approved for adult patients with hypereosinophilic syndrome
(HES) and/or chronic eosinophilic leukemia (CEL), adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans, as well as for adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST) .
GlobalData's clinical trial report, "Hypereosinophilic Syndrome
Global Clinical Trials Review, H2, 2015" provides an overview of Hypereosinophilic Syndrome
clinical trials scenario.
1) It can be either primary (idiopathic) or secondary as a result of systemic conditions such as hypereosinophilic syndrome
, celiac disease, Crohn disease, Churg-Strauss syndrome, and helminthic infection or of drugs such as enalapril, gemfibrozil, cyclosporine, naproxen, clozapine, rifampicin and gold.
17) Eosinophilia may be observed in: (1) benign reactive eosinophilia, (2) eosinophilia of miscellaneous malignant disorders, and (3) sustained idiopathic eosinophilia, including idiopathic hypereosinophilic syndrome
and eosinophilic leukemia.
Global Markets Direct's, 'Hypereosinophilic Syndrome
- Pipeline Review, H1 2012', provides an overview of the Hypereosinophilic Syndrome